ersodetug
ersodetug: developed by 1 company · 1 clinical trial tracked.
ersodetug evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could ersodetug → RZLT affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Rezolute, Inc. (RZLT) Tumor Hyperinsulinism (Tumor HI) | Phase 3 |
Clinical Trials (1)
A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Compared to Baseline in Patients With Inadequately Controlled Hypoglycemia Due to Tumor Hyperinsulinism (Tumor HI)
Primary endpoint: Proportion of participants with clinically meaningful reduction in IV glucose infusion rate from baseline.
Frequently asked questions
Who is developing ersodetug?
ersodetug is being developed by Rezolute, Inc..
How many clinical trials involve ersodetug?
BioSniper tracks 1 clinical trial involving ersodetug.